American Diabetes Association

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.

The expanded indication provides an important treatment option for clinicians and patients with type 1 diabetes.

The investigative GLP-1 receptor agonist was compared to liraglutide, sitagliptin, and placebo in adult patients with type 2 diabetes.

Human antibody may substantially reduce need for insulin in patients with T1D.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.

More than 3,000 original research presentations will be offered in a robust 5-day program.

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

The field of diabetes care is continually moving forward. Even as data was being presented at this year's meeting of the American Diabetes Association the future was at the forefront of many people's minds in an effort to help these patients even more.

There is no question that hunger can affect a person's life, a recent study looked at the scientific aspect of this discussion and what doctors can do to help patients with this challenge.

The obesity epidemic continues to grow in this country leaving the medical community to find new ways to help this patient population.

A fair amount of women who are diagnosed with gestational diabetes take active measures to lose weight – but what clinical outcomes does that have?

What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

Diabetic kidney disease does not have the telltale signs of other conditions which can make it difficult to spot. However, with the right tests patients can get the treatments they need.

One of the newest developments in the treatment of diabetes is the GLP-1 receptor agonist. With different forms intended for different populations it continues a longstanding pattern of bringing new medications into the pool of options for doctors to choose from.

As the diabetes epidemic continues to grow doctors are being faced with the task of stopping or reversing the trend.

Study results show that the combination of metformin and glibenclamide is as effective as insulin in achieving glycemic control in women with gestational diabetes and may be a more acceptable and cost effective therapy.

Empagliflozin, a diabetes drug that controls glucose levels, may also help ameliorate erectile dysfunction in patients with type 2 diabetes mellitus.

Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.

Real-time blood sugar and insulin infusion data displayed in the electronic medical record allows physicians to tailor treatment and get more patients to goal.

Dr. Trevor Orchard previews what he will be discussing during his presentation on cardiovascular disease in patients with type 1 diabetes at the ADA meeting.